Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed mod...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medicinal chemistry Vol. 69; pp. 77 - 89
Main Authors Tang, Qidong, Zhao, Yanfang, Du, Xinming, Chong, Lian'e, Gong, Ping, Guo, Chun
Format Journal Article
LanguageEnglish
Published ISSY-LES-MOULINEAUX Elsevier Masson SAS 01.11.2013
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC50] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure–activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity. [Display omitted] Two series of quinoline derivatives bearing pyridine/pyrimidine scaffolds were synthesized and evaluated for their cytotoxic activities. Seven potent compounds were further examined for their c-Met kinase activity. •Two series of quinoline derivatives were designed and synthesized.•The target compounds showed potent antitumor activity.•Seven compounds were further examined for their c-Met kinase activity.•The cytotoxicity of 18b was 7.3-fold higher against HT-29 cells than foretinib.•Compound 18b showed an IC50 value of 1.39 nM against c-Met kinase.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2013.08.019